Advances in phase Ⅲ vaccines against non-small cell lung cancer

Lung cancer is the leading cause of cancer-related death in the world and greatly threatens the health and life of people. Targeted therapy has not improved the 5-year survival rate of lung cancer patients, although it demonstrates certain anti-tumor effects. Active-specific immunotherapy develops rapidly in recent years and curative effects of certain anti-cancer vaccines have been approved, it is still in its infancy. Following is a review of the recent developments in phase Ⅲ vaccines against non-small cell lung cancer (NSCLC).